{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:01:34Z","timestamp":1791489694687,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Galectin-3 is a biomarker of heart disease. However, it remains unknown whether increase in galectin-3 levels is dependent on aetiology or disease-associated conditions and whether diseased heart releases galectin-3 into the circulation. We explored these questions in mouse models of heart disease and in patients with cardiomyopathy. All mouse models (dilated cardiomyopathy, DCM; fibrotic cardiomyopathy, ischemia-reperfusion, I\/R; treatment with \u03b2-adrenergic agonist isoproterenol) showed multi-fold increases in cardiac galectin-3 expression and preserved renal function. In mice with fibrotic cardiomyopathy, I\/R or isoproterenol treatment, plasma galectin-3 levels and density of cardiac inflammatory cells were elevated. These models also exhibited parallel changes in cardiac and plasma galectin-3 levels and presence of trans-cardiac galectin-3 gradient, indicating cardiac release of galectin-3. DCM mice showed no change in circulating galectin-3 levels nor trans-cardiac galectin-3 gradient or myocardial inflammatory infiltration despite a 50-fold increase in cardiac galectin-3 content. In patients with hypertrophic cardiomyopathy or DCM, plasma galectin-3 increased only in those with renal dysfunction and a trans-cardiac galectin-3 gradient was not present. Collectively, this study documents the aetiology-dependency and diverse mechanisms of increment in circulating galectin-3 levels. Our findings highlight cardiac inflammation and enhanced \u03b2-adrenoceptor activation in mediating elevated galectin-3 levels via cardiac release in the\u00a0mechanism.<\/jats:p>","DOI":"10.1038\/s41598-018-26115-y","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T11:57:41Z","timestamp":1526990261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure"],"prefix":"10.1038","volume":"8","author":[{"given":"My-Nhan","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Vizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andris H.","family":"Ellims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Bo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kiriazis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Sadoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"McMullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Dart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"26115_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nri2536","volume":"9","author":"GA Rabinovich","year":"2009","unstructured":"Rabinovich, G. A. & Toscano, M. A. Turning \u2018sweet\u2019 on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol. 9, 338\u201352 (2009).","journal-title":"Nat Rev Immunol."},{"key":"26115_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/CIRCHEARTFAILURE.112.000129","volume":"6","author":"AR van der Velde","year":"2013","unstructured":"van der Velde, A. R. et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 6, 219\u2013226 (2013).","journal-title":"Circ Heart Fail."},{"key":"26115_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/srep34357","volume":"6","author":"N Clementy","year":"2016","unstructured":"Clementy, N. et al. Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation. Sci Rep. 6, 34357 (2016).","journal-title":"Sci Rep."},{"key":"26115_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/jce.12364","volume":"25","author":"P Francia","year":"2014","unstructured":"Francia, P. et al. Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators. J Cardiovasc Electrophysiol. 25, 609\u2013616 (2014).","journal-title":"J Cardiovasc Electrophysiol."},{"key":"26115_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/srep40378","volume":"7","author":"D Hernandez-Romero","year":"2017","unstructured":"Hernandez-Romero, D. et al. Galectin-3 as a marker of interstitial atrial remodelling involved in atrial fibrillation. Sci Rep. 7, 40378 (2017).","journal-title":"Sci Rep."},{"key":"26115_CR6","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1161\/HYPERTENSIONAHA.115.05159","volume":"65","author":"E Libhaber","year":"2015","unstructured":"Libhaber, E. et al. Independent associations of circulating galectin-3 concentrations with aortic pulse wave velocity and wave reflection in a community sample. Hypertension. 65, 1356\u20131364 (2015).","journal-title":"Hypertension."},{"key":"26115_CR7","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ahj.2014.02.011","volume":"167","author":"WC Meijers","year":"2014","unstructured":"Meijers, W. C. et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J. 167, 853\u2013860 (2014).","journal-title":"Am Heart J."},{"key":"26115_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep17007","volume":"5","author":"CK Wu","year":"2015","unstructured":"Wu, C. K. et al. Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices. Sci Rep. 5, 17007 (2015).","journal-title":"Sci Rep."},{"key":"26115_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jacbts.2016.03.003","volume":"1","author":"Y Takemoto","year":"2016","unstructured":"Takemoto, Y. et al. Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes. JACC Basic Transl Sci. 1, 143\u2013154 (2016).","journal-title":"JACC Basic Transl Sci."},{"key":"26115_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3109\/07853890.2010.538080","volume":"43","author":"RA de Boer","year":"2011","unstructured":"de Boer, R. A. et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 43, 60\u201368 (2011).","journal-title":"Ann Med."},{"key":"26115_CR11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1161\/ATVBAHA.114.304964","volume":"35","author":"G Maiolino","year":"2015","unstructured":"Maiolino, G. et al. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 35, 725\u2013732 (2015).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"26115_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12872-016-0290-7","volume":"16","author":"F Stoltze Gaborit","year":"2016","unstructured":"Stoltze Gaborit, F. et al. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. BMC Cardiovasc Disord. 16, 117 (2016).","journal-title":"BMC Cardiovasc Disord."},{"key":"26115_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jchf.2014.10.009","volume":"3","author":"OF AbouEzzeddine","year":"2015","unstructured":"AbouEzzeddine, O. F. et al. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). JACC Heart Fail. 3, 245\u2013252 (2015).","journal-title":"JACC Heart Fail."},{"key":"26115_CR14","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1373\/clinchem.2016.257550","volume":"62","author":"H Jansen","year":"2016","unstructured":"Jansen, H. et al. Prognostic Utility of Galectin-3 for Recurrent Cardiovascular Events During Long-term Follow-up in Patients with Stable Coronary Heart Disease: Results of the KAROLA Study. Clin Chem. 62, 1372\u20131379 (2016).","journal-title":"Clin Chem."},{"key":"26115_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1159\/000445103","volume":"134","author":"EG Singsaas","year":"2016","unstructured":"Singsaas, E. G., Manhenke, C. A., Dickstein, K. & Orn, S. Circulating Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction. Cardiology. 134, 398\u2013405 (2016).","journal-title":"Cardiology."},{"key":"26115_CR16","doi-asserted-by":"crossref","unstructured":"Besler C. et al. Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker. Circ Heart Fail. 10 (2017).","DOI":"10.1161\/CIRCHEARTFAILURE.116.003804"},{"key":"26115_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/eurjhf\/hfr151","volume":"14","author":"N Lopez-Andres","year":"2012","unstructured":"Lopez-Andres, N. et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail. 14, 74\u201381 (2012).","journal-title":"Eur J Heart Fail."},{"key":"26115_CR18","doi-asserted-by":"publisher","first-page":"e0123574","DOI":"10.1371\/journal.pone.0123574","volume":"10","author":"J Kornej","year":"2015","unstructured":"Kornej, J. et al. Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. PLoS One. 10, e0123574 (2015).","journal-title":"PLoS One."},{"key":"26115_CR19","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.hrthm.2014.07.007","volume":"11","author":"QA Truong","year":"2014","unstructured":"Truong, Q. A. et al. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. Heart Rhythm. 11, 2167\u20132175 (2014).","journal-title":"Heart Rhythm."},{"key":"26115_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ejhf.246","volume":"17","author":"B Lopez","year":"2015","unstructured":"Lopez, B. et al. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail. 17, 385\u2013392 (2015).","journal-title":"Eur J Heart Fail."},{"key":"26115_CR21","doi-asserted-by":"publisher","first-page":"e000760","DOI":"10.1161\/JAHA.112.000760","volume":"1","author":"DM Gopal","year":"2012","unstructured":"Gopal, D. M. et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc. 1, e000760 (2012).","journal-title":"J Am Heart Assoc."},{"key":"26115_CR22","doi-asserted-by":"publisher","first-page":"e000962","DOI":"10.1161\/JAHA.114.000962","volume":"3","author":"WC Meijers","year":"2014","unstructured":"Meijers, W. C. et al. Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. J Am Heart Assoc. 3, e000962 (2014).","journal-title":"J Am Heart Assoc."},{"key":"26115_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijcard.2014.09.011","volume":"177","author":"E Zamora","year":"2014","unstructured":"Zamora, E. et al. Renal function largely influences Galectin-3 prognostic value in heart failure. Int J Cardiol. 177, 171\u2013177 (2014).","journal-title":"Int J Cardiol."},{"key":"26115_CR24","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1681\/ASN.2014010093","volume":"26","author":"C Drechsler","year":"2015","unstructured":"Drechsler, C. et al. Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies. J Am Soc Nephrol. 26, 2213\u20132221 (2015).","journal-title":"J Am Soc Nephrol."},{"key":"26115_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIRCRESAHA.116.308030","volume":"119","author":"SA Dick","year":"2016","unstructured":"Dick, S. A. & Epelman, S. Chronic Heart Failure and Inflammation: What Do We Really Know? Circ Res. 119, 159\u2013176 (2016).","journal-title":"Circ Res."},{"key":"26115_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1042\/CS20100011","volume":"119","author":"L Fang","year":"2010","unstructured":"Fang, L., Du, X. J., Gao, X. M. & Dart, A. M. Activation of peripheral blood mononuclear cells and extracellular matrix and inflammatory gene profile in acute myocardial infarction. Clin Sci (Lond). 119, 175\u2013183 (2010).","journal-title":"Clin Sci (Lond)."},{"key":"26115_CR27","first-page":"1409","volume":"52","author":"WF Peacock","year":"2014","unstructured":"Peacock, W. F. How galectin-3 changes acute heart failure decision making in the emergency department. Clin Chem Lab Med. 52, 1409\u20131412 (2014).","journal-title":"Clin Chem Lab Med."},{"key":"26115_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/0735-1097(94)90738-2","volume":"23","author":"DM Kaye","year":"1994","unstructured":"Kaye, D. M. et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol. 23, 570\u2013578 (1994).","journal-title":"J Am Coll Cardiol."},{"key":"26115_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jchf.2014.08.002","volume":"3","author":"L Calvier","year":"2015","unstructured":"Calvier, L. et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 3, 59\u201367 (2015).","journal-title":"JACC Heart Fail."},{"key":"26115_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","volume":"33","author":"L Calvier","year":"2013","unstructured":"Calvier, L. et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 33, 67\u201375 (2013).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"26115_CR31","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.ajpath.2015.12.017","volume":"186","author":"O Frunza","year":"2016","unstructured":"Frunza, O. et al. Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis. Am J Pathol. 186, 1114\u20131127 (2016).","journal-title":"Am J Pathol."},{"key":"26115_CR32","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1161\/HYPERTENSIONAHA.115.05876","volume":"66","author":"E Martinez-Martinez","year":"2015","unstructured":"Martinez-Martinez, E. et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension. 66, 767\u2013775 (2015).","journal-title":"Hypertension."},{"key":"26115_CR33","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","volume":"110","author":"UC Sharma","year":"2004","unstructured":"Sharma, U. C. et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 110, 3121\u20133128 (2004).","journal-title":"Circulation."},{"key":"26115_CR34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","volume":"6","author":"L Yu","year":"2013","unstructured":"Yu, L. et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 6, 107\u2013117 (2013).","journal-title":"Circ Heart Fail."},{"key":"26115_CR35","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.yjmcc.2010.12.022","volume":"50","author":"XM Gao","year":"2011","unstructured":"Gao, X. M. et al. Deletion of macrophage migration inhibitory factor protects the heart from severe ischemia-reperfusion injury: a predominant role of anti-inflammation. J Mol Cell Cardiol. 50, 991\u2013999 (2011).","journal-title":"J Mol Cell Cardiol."},{"key":"26115_CR36","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1161\/ATVBAHA.110.220467","volume":"31","author":"Y Liu","year":"2011","unstructured":"Liu, Y. et al. Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction. Arterioscler Thromb Vasc Biol. 31, 834\u2013841 (2011).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"26115_CR37","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1126\/science.1175202","volume":"325","author":"FK Swirski","year":"2009","unstructured":"Swirski, F. K. et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 325, 612\u2013616 (2009).","journal-title":"Science."},{"key":"26115_CR38","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.jacc.2016.01.073","volume":"67","author":"PC Westman","year":"2016","unstructured":"Westman, P. C. et al. Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction. J Am Coll Cardiol. 67, 2050\u20132060 (2016).","journal-title":"J Am Coll Cardiol."},{"key":"26115_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1161\/ATVBAHA.107.159160","volume":"28","author":"M Papaspyridonos","year":"2008","unstructured":"Papaspyridonos, M. et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol. 28, 433\u2013440 (2008).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"26115_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cca.2015.10.034","volume":"452","author":"AR van der Velde","year":"2016","unstructured":"van der Velde, A. R. et al. Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clin Chim Acta. 452, 50\u201357 (2016).","journal-title":"Clin Chim Acta."},{"key":"26115_CR41","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1172\/JCI17459","volume":"111","author":"S Yamamoto","year":"2003","unstructured":"Yamamoto, S. et al. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J Clin Invest. 111, 1463\u20131474 (2003).","journal-title":"J Clin Invest."},{"key":"26115_CR42","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S0008-6363(00)00187-5","volume":"48","author":"XJ Du","year":"2000","unstructured":"Du, X. J. et al. Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing \u03b22-adrenergic receptors in the heart. Cardiovasc Res. 48, 448\u2013454 (2000).","journal-title":"Cardiovasc Res."},{"key":"26115_CR43","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","volume":"175","author":"L Pretorius","year":"2009","unstructured":"Pretorius, L. et al. Reduced phosphoinositide 3-kinase (p110\u03b1) activation increases the susceptibility to atrial fibrillation. Am J Pathol. 175, 998\u20131009 (2009).","journal-title":"Am J Pathol."},{"key":"26115_CR44","doi-asserted-by":"crossref","first-page":"H946","DOI":"10.1152\/ajpheart.00405.2015","volume":"309","author":"MN Nguyen","year":"2015","unstructured":"Nguyen, M. N. et al. Spontaneous ventricular tachyarrhythmias in \u03b22-adrenoceptor transgenic mice in relation to cardiac interstitial fibrosis. Am J Physiol Heart Circ Physiol. 309, H946\u2013H957 (2015).","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"26115_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1532-429X-14-76","volume":"14","author":"AH Ellims","year":"2012","unstructured":"Ellims, A. H. et al. Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J Cardiovasc Magn Reson. 14, 76 (2012).","journal-title":"J Cardiovasc Magn Reson."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26115-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26115-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26115-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T05:49:22Z","timestamp":1671601762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26115-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["26115"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-26115-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"16 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8213"}}